retatrutide phase 2 study results Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, 2 trial conducted in the USA Looking forward to when #retatrutide's

2023 Jan;123(1):117143

At DrHouse, every patient starting a GLP-1 gets a baseline panel: comprehensive metabolic panel, complete blood count, thyroid panel, lipid panel, hemoglobin A1C, urinalysis, and a pregnancy test for female patients

Let's be reallosing muscle isn't just about aesthetics

These medications, which are used primarily for T2D management, have shown beneficial effects on both cardiac and renal diseases

By modulating both the innate and adaptive arms of the immune system, Thymosin Alpha-1 has shown incredible promise in fields as diverse as infectious disease/infectious medicine, oncology, healthy aging, and functional medicine

Listen to our episodes that focus on the hot topic of GLP-1s and chronic weight management